Study of MeRes100 in the Treatment of Patient With Coronary Artery Disease.
A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 484 participants.
Also called NCT03454724
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 484 participants
- Registry
-
NCT03454724
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT03454724. Randomized; no masking; primary purpose treatment. Start 2020-01-01 (anticipated); primary completion 2020-12-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of MeRes100 in the Treatment of Patient With Coronary Artery Disease.
- Acronym
- MeReS100-China
- Condition
- Coronary Artery Disease
- Intervention (Device)
- MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System
- Intervention (Device)
- Xience EES Everolimus Eluting Coronary Stent System
- Lead sponsor
- Meril Life Sciences Pvt. Ltd.
Record details
- Record id
cardio:ct-nct03454724- Content hash
57d37e1c9630f7b031f7856e61b3716a28287f4d251a36fd143adc73d1a2e903